The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Neuroprotection: a recent clinical study presented the first evidence in humans of GLP1-RA outperforming other treatment options in preventing the onset of Alzheimer disease in type-2 diabetes patients. This is also the first evidence of GLP1-RAs reducing the risk of an age-related disease independent of obesity and weight reduction (3).
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
More recent evidence suggests a potential for GLP-1 agonists in preventing age related disease in non-obese people too, as was demonstrated that its effect in reducing Alzheimer disease risk outweighed all other diabetes medications with similar risk reduction in normal weight and obese participants (3).